A5101987351- Immunotherapy and Immune Responses
- Cytomegalovirus and herpesvirus research
- Hepatitis B Virus Studies
- Hepatitis C virus research
- HIV Research and Treatment
- Cancer Research and Treatments
- Immune Cell Function and Interaction
- Hepatitis Viruses Studies and Epidemiology
- Viral gastroenteritis research and epidemiology
- Herpesvirus Infections and Treatments
- Glioma Diagnosis and Treatment
- SARS-CoV-2 and COVID-19 Research
- RNA Interference and Gene Delivery
- Advanced Drug Delivery Systems
- Cancer Immunotherapy and Biomarkers
- MicroRNA in disease regulation
- Advancements in Transdermal Drug Delivery
- T-cell and B-cell Immunology
- CAR-T cell therapy research
- vaccines and immunoinformatics approaches
- Nanoplatforms for cancer theranostics
- Virus-based gene therapy research
- Respiratory viral infections research
- Parvovirus B19 Infection Studies
- Cell Adhesion Molecules Research
Variation Biotechnologies (Canada)
2006-2023
Dana-Farber Cancer Institute
2019
Instituto Tecnológico de Santo Domingo
2016
Variation Reduction Solutions (United States)
2013
The University of Texas MD Anderson Cancer Center
2009-2011
Brigham and Women's Hospital
2001-2010
Harvard University
2001-2010
Urology Associates
2005
Children's Cancer Center
2005
University of California, Davis
1993-2001
Oral vaccines offer significant benefits due to the ease of administration, better patient compliance and non-invasive, needle-free administration. However, this route is marred by harsh gastro intestinal environment which detrimental many vaccine formats. To address this, a range delivery systems have been considered including bilosomes; these are bilayer vesicles constructed from non-ionic surfactants combined with inclusion bile salts can stabilize in tract preventing membrane...
ABSTRACT A prophylactic vaccine to prevent the congenital transmission of human cytomegalovirus (HCMV) in newborns and reduce life-threatening disease immunosuppressed recipients HCMV-infected solid organ transplants is highly desirable. Neutralizing antibodies against HCMV confer significant protection infection, glycoprotein B (gB) a major target such neutralizing antibodies. However, one shortcoming past vaccines may have been their failure induce high-titer persistent antibody responses...
<h3>Importance</h3> There is a need for improved immunogenicity of hepatitis B virus (HBV) vaccines among young adults with risk infection. <h3>Objectives</h3> To demonstrate manufacturing equivalence 3-antigen (3A) HBV vaccine, evaluate noninferiority seroprotection rate (SPR) 3A-HBV vs single-antigen (1A) after 2 and 3 vaccine doses, compare safety reactogenicity between 1A-HBV vaccines. <h3>Design, Setting, Participants</h3> This phase 3, double-blinded, randomized clinical trial included...
We evaluated enveloped virus-like particles (eVLPs) expressing various forms of the Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein and several adjuvants in an effort to identify a highly potent Coronavirus disease 2019 (COVID-19) vaccine candidate. eVLPs modified prefusion form SARS-CoV-2 were selected as they induced high antibody binding titers neutralizing activity after single injection mice. Formulation S with aluminum phosphate resulted balanced induction...
Prevention of hepatitis B virus (HBV) infection by vaccination can potentially eliminate HBV-related diseases. PreHevbrio™/PreHevbri® is a 3-antigen (S, preS1, preS2) HBV vaccine (3A-HBV) recently licensed for adults in the US, EU and Canada. This study evaluated antibody persistence subset fully vaccinated seroprotected (anti-HBs ≥ 10 mIU/mL) Finnish participants from phase 3 trial (PROTECT) 3A-HBV versus single-antigen (1A-HBV). 465/528 eligible subjects were enrolled (3A-HBV: 244; 1A-HBV:...
Cytomegalovirus (CMV) is the most common cause of congenital infection and affected children often have permanent neurodevelopmental sequelae, including hearing loss intellectual disability. Vaccines to prevent transmission CMV during pregnancy are a public health priority. This first-in-humans dose-ranging, randomized, placebo-controlled, observer-blinded study evaluated safety immunogenicity an enveloped virus-like particle (eVLP) vaccine expressing modified form glycoprotein B (gB).
One of the major obstacles in design an effective vaccine against HIV-1 is its antigenic variation, which results viral escape from immune system. Through a bioinformatics approach, we developed innovative multivalent comprised pool 176 lipidated and nonlipidated peptides representing variable regions Env Gag proteins. The potency breadth candidate panel subtypes was evaluated nonhuman primate (cynomolgus macaques) humanized mouse (HLA-A2.1) models. demonstrate strong immunogenicity with...
Within this work, we develop vesicles incorporating sub-unit antigens as solid dosage forms suitable for the oral delivery of vaccines. Using a combination trehalose, dextran and mannitol, freeze-dried disintegrating tablets were formed which upon rehydration release bilayer antigen. Initial studies focused on optimisation freeze-dry cycle subsequently excipient content was optimised by testing tablet hardness, disintegration time moisture content. The use 10% mannitol produced durable...
SIVmac infection of macaques is an important animal model for HIV and AIDS; this being utilized development antiviral therapies vaccines. In the present article, we sought to identify neutralization epitopes envelope surface glycoprotein (gp130). Algorithms were used predict antigenicity specific regions. Four regions from primary amino acid sequence viral selected. A synthetic peptide representing one these (414-434) induced virusneutralizing antibodies in mice; addition, T...
Sci-B-Vac® is a tri-antigenic recombinant Hepatitis B vaccine (TAV) containing the small (s), medium (pre-S2) and large (pre-S1) hepatitis surface (HBs) antigens. To comply with licensure, new reference standard batch was qualified by characterizing seroprotection rate (SPR) for anti-HBs titers ≥10 mIU/mL, following vaccination. Ninety-one healthy adults aged 20–40 years were enrolled in an open label, single-arm phase IV study receiving three IM doses of 10 μg TAV at 0, 1 6 months....
One of the major obstacles in design an effective vaccine against HIV-1 is hypervariability envelope glycoprotein. Most candidates have utilized glycoprotein from a single virus isolate, but to date, none them elicited broadly reactive humoral immunity. Herein, we hypothesised that cocktail gp120 proteins containing multiple epitopes may increase breadth immune responses HIV-1. We compared and evaluated immunogenicity vaccines either protein alone or combinations four fourteen gp120s...
Current treatments for hepatitis C infection have limited efficacy, and there is no vaccine available. The goal of this study was to compare the immune response several immunization combinations against virus (HCV). Six groups mice were immunized at weeks 0, 4, 8 with different a candidate HCV consisting 100 µg recombinant core/E1/E2 (rHCV) DNA plasmid and/or 25 rHCV polyprotein 50 µL Montanide ISA- 51. Four after last injection, all sacrificed blood samples spleens collected measuring...
2047 Background: Cytomegalovirus (CMV) antigens have been reported in over 90% of GBMs. CD4 + and CD8 T cells are most frequently directed against the gB pp65 antigens, respectively, immunogenic targets a CMV-based GBM vaccine. Methods: We enrolled total 20 patients with KPS at least 70 first recurrence into 2 arms Phase IIa extension gB/pp65 enveloped virus-like particles (eVLPs) adjuvanted either GM-CSF given intradermally or AS01 B intramuscularly (NCT03382977). Patients were vaccinated...
Immune responses against hepatitis C virus (HCV) have been studied by numerous groups. However, details concerning the production of antibodies to antigenically variable epitopes remain be elucidated. Since sequences regions several HCV proteins are different among strains infecting patients, we decided design peptide combinations that represent theoretical maximum antigenic variation each epitope used as capture antigens. We prepared six mixtures (hypervariable constructs; HECs)...
The slow growth of hepatitis A virus (HAV) in cell culture is one the primary pitfalls development sensitive and rapid methods for detection quantification HAV associated neutralizing antibodies. Currently, vitro assays frequently require 8 days or more to detect quantify presence This study describes a immunoassay that allowed anti-HAV antibodies only 3 days. microplate-based enzymic assay may be applicable virological diagnostics, evaluating immunogenicity vaccines quantifying during...
Abstract Background CMV is the most common cause of congenital infection and may result in permanent neurodevelopmental injury including vision hearing loss. A vaccine to prevent transmission during pregnancy or immunocompromised persons a public health priority. Neutralizing antibodies (nAb) envelope glycoprotein B (gB) natural are thought confer protection, but some candidates based on this protein alone have been insufficiently immunogenic. In FiH dose-ranging, controlled,...
A limitation of past immunotherapeutic vaccines against glioblastoma multiforme (GBM) and medulloblastoma (MED) has been the difficulty in inducing a potent tumor-specific response, due part to poor immunogenicity tumor-associated antigens, means formulation/delivery vaccine, or combination both. Human cytomegalovirus (CMV) is ubiquitous, generally asymptomatic virus that present over 90% GBM MED tumors. Memory CD4+ CD8+T cells are most frequently directed gB pp65 respectively. Thus, CMV...
Abstract Cytomegalovirus (CMV) antigens have been reported in over 90% of GBMs. CD4+ and CD8+ T cells are most frequently directed against the gB pp65 antigens, respectively, which immunogenic targets a CMV-based GBM immunotherapeutic. First-recurrent patients were enrolled, with Karnofsky Performance Status at least 70, to receive VBI-1901 (a gB/pp65 enveloped virus-like particle [eVLP]) adjuvanted GM-CSF given intradermally (NCT03382977). Patients vaccinated every 4 weeks, surveillance...
Abstract Cytomegalovirus (CMV) antigens have been reported in over 90% of GBMs. CD4+ and CD8+ T cells are most frequently directed against the gB pp65 antigens, respectively, which immunogenic targets a CMV-based GBM immunotherapeutic. First-recurrent patients with KPS³70 received VBI-1901 (a gB/pp65 enveloped virus-like particle [eVLP]) adjuvanted GM-CSF intradermally (NCT03382977). Patients q4w, serologic immune-monitoring q2w after each vaccination surveillance brain MRI scans q6w. Among...
Abstract Rapid emergence of SARS-CoV-2 variants is a constant threat and major hurdle to reach heard immunity. We produced VBI-2905a, an enveloped virus-like particle (eVLP)-based vaccine candidate expressing prefusion spike protein from the Beta variant that contains several escape mutations. VBI-2905a protected hamsters against infection with virus induced high levels neutralizing antibodies RBD. In heterologous vaccination regimen, single injection in animals previously immunized...
2048 Background: Cytomegalovirus (CMV) antigens have been reported in over 90% of GBM tumors. CD4 + and CD8 T cells are most frequently directed against the gB pp65 antigens, respectively, immunogenic targets a CMV-based vaccine. Methods: We initiated phase I/IIa clinical trial for patients with recurrent using gB/pp65 enveloped virus-like particles (eVLPs) formulated GM-CSF administered intradermally. Subjects vaccinated monthly until tumor progression, immunomonitoring performed 2 weeks...
Abstract Development of efficacious single dose vaccines would substantially aid efforts to stop the uncontrolled spread COVID-19 pandemic. We evaluated enveloped virus-like particles (eVLPs) expressing various forms SARS-CoV-2 spike protein and several adjuvants in an effort identify a vaccine candidate after dose. The eVLPs modified prefusion form were selected as they induced highest antibody binding titers neutralizing activity injection mice. Formulation S with aluminum phosphate...